Buradasınız

Anasayfa » Content

Statinlerin Böbrek İşlevleri Üzerine Etkisi

The Effects of Statins on Renal Functions

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2005

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Lipid metabolism disorder results in progression of chronic renal disease. Statins inhibit HMG-CoA reductase, that catalyzes the rate-limiting step in cholesterol biosynthesis and statins also dec¬rease clinical risks related with atherosclerosis. In addition to lipid-lowering effects, a multitude of potentially renal protective effects are being ascribed to statins in recent reports, including improved endothelial function, increased plaque stability, decreased monocyte migration, decreased mesengial matrix proliferation, and improved circulation. In this review, the pathogenesis of beneficial effect of statins are well examined and we present the reports which were investi¬gated the effects of statins on renal functions.
Bookmark/Search this post with
Abstract (Original Language): 
Lipid metabolizmas ı ile ilgili bozukluklar süreğen böbrek hastalıklarının oluşumunda ve ilerlemesinde önemli bir yere sahiptir. Statinler kolesterol sentezinde hız kısıtlayıcı enzimi inhibe ederek kolesterol düzeyini düşürmekte ve aterosklerotik hastalığın her türlü klinik riskini azaltmaktadır. Statinlerin renal hemodinami, endo-tel fonksiyonu üzerine olan yararlı etkileri, monosit göçünü engellemeleri, mezengiyal hücre çoğalmasını, matriks yoğunlaşmasını önlemeleri ve plak stabilitesini sağlamaları sonucunda süreğen böbrek hastalıklarının ilerlemesini yavaşlattıkları yapılan çalışmalarda gösterilmiştir. Bu derlemede statin tedavisinin olumlu etkilerinin patogenezi incelenmiş ve statin tedavisinin böbrek işlevleri üzerine olan etkilerinin araştırıldığı çalışmalar özetlenmiştir.
FULL TEXT (PDF): 
PDF icon pdf_tndt_530.pdf
  • 3
103-107
  • Turkish

REFERENCES

References: 

1. Endo A. The discovery and development of HMG-Co A reductase inhibitors. J Lipid Res 1992;33:1569-82.
2. Bilheilmer DW, Grundy SM, Brown MS, Goldstein JL. Mevi-lonin and colestipol stimulate receptor-mediated clearence of low density lipoprotein in familial hypercholesterolemia he-terozygotes. Proc Natl Acad Sci USA 1983;150:1313-9.
3. La Rosa JC, He J, Vuuppturi S. Effect of statins on risk of co¬ronary disease; metaanalysis of randomized controlled trials.
JAMA 1999; 282:2340-6.
4. Long-Term Intervention with Pravastatin in Ischaemic Dise¬ase (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart di¬sease and a broad range of initial cholesterol levels. N Engl J
Med 1998;339:1349-57.
5.
Tür
k Kardiyoloji Seminerleri; Cilt 3, Sayı:5, 615.
6. Stefano Bianchi, Roberto Bigazzi, Alberto Caiazza. a C, Pros¬pective Study of the Effect on Proteinuria and progression of kidney Disease. AJKD, Vol 41, No:3, 2003:565-570.
7. Yang WQ, Song NG, Ying SS, et al. Serum lipid concentrati¬ons correlate with the progression of chronic renal failure.
Clin Lab Sci 1999;12:104-108.
8. Oda H, Keane WF. Recent advances in statins and the kid¬ney. Kidney Int Suppl 71 :S2-S5,1999.
9. Davignon J. Methods and endpoint issues in clinical develop¬ment of lipid acting agents with pleiotropic effects. Am J Car-
diol 81: 8A:17 F-23 F, 1988.
10. Schonbeck U, Libby P. CD40 signalling and plaque instability. Circ Res 2001;89:1092-1103.
106
Türk
Nefroloj
i Diyaliz ve Transplantasyon Dergisi /Official Journal of the Turkish Society of Nephrology
Statinlerin Böbrek İşlevleri Üzerine Etkisi O
11. Rabbani R, Topol EJ. Strategies to achieve coronary arterial plaque stabilization. Cardiov Research 1999;41:402-17.
12. Mantarri M, Tiula E, Alikoski T. Effect of hypertension and dyslipidemia on the decline in renal function. Hypertension
1995;26:670-675.
13. Schaeffner E, Kurth T, Curhan G. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Neph-rol 2003;14:2084-2091.
14. Muntner P, Coresh J, Smith JC. Plasma lipids and risk of de¬veloping renal dysfunction: The Atherosclerosis Risk in Com¬munities Study. Kidney International 2000, Vol. 58, 293-301.
15. Carruthers KF, Dabbous OH, Flather MD, Starkey I, Jacob A, Macleod D,
Fo
x KA. Contemporary management of acute coronary syndromes: does the practice match the evidence? The Global Registry of Acute Coronary Events (GRACE). He¬art 2005 Mar; 91(3):290-8.
16. Ridcker PM, Rifai N. Long term effects of pravastatin on plas¬ma concentration of CRP (CARE study); Circulation 1999;
100:230-235.
17. Afzalı B, Haydar A, Vınen K. Beneficial effects of statins for patients with chronic kidney disease. J Am Soc Nephrology
2004;15:2161-2168.
18. Chang J, Yang WS, Min WK. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodi-
alysis patients. AJKD 2002;Vol 39;No 6:1213-1217.
19. Koh KK. Effects of statins vascular wall: Vasomotor function, inflammation and plaque stability. Cardiov Research 2000;47:
648-57.
20. Yoshino G, Hirano T, Kazumi T. Fluvastatin increases LDL particle size and reduces oxidative stress in patients with hyperlipidemia. J Atheroscler Thromb 2003; Vol.10, No 6:
343-347.

Thank you for copying data from http://www.arastirmax.com